200 related articles for article (PubMed ID: 33601250)
41. Establishing the Medical Actionability of Genomic Variants.
Goddard KAB; Lee K; Buchanan AH; Powell BC; Hunter JE
Annu Rev Genomics Hum Genet; 2022 Aug; 23():173-192. PubMed ID: 35363504
[TBL] [Abstract][Full Text] [Related]
42. The future of cancer treatment using precision oncogenomics.
Wartman LD
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610395
[TBL] [Abstract][Full Text] [Related]
43. Next-generation sequencing: from conventional applications to breakthrough genomic analyses and precision oncology.
Ziogas DE; Kyrochristos ID; Roukos DH
Expert Rev Med Devices; 2018 Jan; 15(1):1-3. PubMed ID: 29284319
[No Abstract] [Full Text] [Related]
44. Integrating precision cancer medicine into healthcare-policy, practice, and research challenges.
Bertier G; Carrot-Zhang J; Ragoussis V; Joly Y
Genome Med; 2016 Oct; 8(1):108. PubMed ID: 27776531
[TBL] [Abstract][Full Text] [Related]
45. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
[TBL] [Abstract][Full Text] [Related]
46. Is Personalized Medicine Here?
Carneiro BA; Costa R; Taxter T; Chandra S; Chae YK; Cristofanilli M; Giles FJ
Oncology (Williston Park); 2016 Apr; 30(4):293-303, 307. PubMed ID: 27085327
[TBL] [Abstract][Full Text] [Related]
47. Genomics in Hematology and Oncology Practice.
Srkalovic G
Acta Med Acad; 2019 Apr; 48(1):1-5. PubMed ID: 31264428
[No Abstract] [Full Text] [Related]
48. Clinical and Technical Aspects of Genomic Diagnostics for Precision Oncology.
Sheikine Y; Kuo FC; Lindeman NI
J Clin Oncol; 2017 Mar; 35(9):929-933. PubMed ID: 28297627
[TBL] [Abstract][Full Text] [Related]
49. Genomic sequencing in oncology: Considerations for integration in routine cancer care.
Rahman B; Lamb A; Protheroe A; Shah K; Solomons J; Williams J; Ormondroyd E
Eur J Cancer Care (Engl); 2022 May; 31(3):e13584. PubMed ID: 35383404
[No Abstract] [Full Text] [Related]
50. The era of precision oncogenomics.
Carpten JC; Mardis ER
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610397
[No Abstract] [Full Text] [Related]
51. Understanding the Precision in "Precision Medicine".
Chabner BA
Oncologist; 2016 Sep; 21(9):1029-30. PubMed ID: 27566249
[TBL] [Abstract][Full Text] [Related]
52. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.
Suehnholz SP; Nissan MH; Zhang H; Kundra R; Nandakumar S; Lu C; Carrero S; Dhaneshwar A; Fernandez N; Xu BW; Arcila ME; Zehir A; Syed A; Brannon AR; Rudolph JE; Paraiso E; Sabbatini PJ; Levine RL; Dogan A; Gao J; Ladanyi M; Drilon A; Berger MF; Solit DB; Schultz N; Chakravarty D
Cancer Discov; 2024 Jan; 14(1):49-65. PubMed ID: 37849038
[TBL] [Abstract][Full Text] [Related]
53. Current Oncology: A Multidisciplinary Medium for Clinical Oncology.
Gill S
Curr Oncol; 2020 Nov; 28(1):2-3. PubMed ID: 33704111
[TBL] [Abstract][Full Text] [Related]
54. Integrating proteomics into precision oncology.
Wahjudi LW; Bernhardt S; Abnaof K; Horak P; Kreutzfeldt S; Heining C; Borgoni S; Becki C; Berg D; Richter D; Hutter B; Uhrig S; Pfütze K; Leichsenring J; Glimm H; Brors B; von Kalle C; Stenzinger A; Korf U; Fröhling S; Wiemann S
Int J Cancer; 2021 Mar; 148(6):1438-1451. PubMed ID: 32949162
[TBL] [Abstract][Full Text] [Related]
55. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
Doble B
Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
[TBL] [Abstract][Full Text] [Related]
56. Challenging Standard-of-Care Paradigms in the Precision Oncology Era.
Subbiah V; Kurzrock R
Trends Cancer; 2018 Feb; 4(2):101-109. PubMed ID: 29458960
[TBL] [Abstract][Full Text] [Related]
57. Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies.
Umelo IA; Costanza B; Castronovo V
Cancer Metastasis Rev; 2018 Mar; 37(1):125-145. PubMed ID: 29392535
[TBL] [Abstract][Full Text] [Related]
58. Cancer genomics: from discovery science to personalized medicine.
Chin L; Andersen JN; Futreal PA
Nat Med; 2011 Mar; 17(3):297-303. PubMed ID: 21383744
[TBL] [Abstract][Full Text] [Related]
59. Moral Duties of Genomics Researchers: Why Personalized Medicine Requires a Collective Approach.
Vos S; van Delden JJM; van Diest PJ; Bredenoord AL
Trends Genet; 2017 Feb; 33(2):118-128. PubMed ID: 28017398
[TBL] [Abstract][Full Text] [Related]
60. Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems.
Normanno N; Apostolidis K; de Lorenzo F; Beer PA; Henderson R; Sullivan R; Biankin AV; Horgan D; Lawler M
Semin Cancer Biol; 2022 Sep; 84():293-301. PubMed ID: 34389490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
